Albany, NY -- (SBWIRE) -- 07/07/2014 -- This report studies the global erectile dysfunction drugs market with a major focus on the branded drugs which include Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil) and others such as MUSE (Medicated Urethral System for Erections), Mvix and Helleva. Pipeline analysis for drugs namely, Vitaros (alprostadil), Uprima (apomorphine) and few others have also been included in the report. Market size and forecasts for the period 2010 – 2019 have been provided for each of the drugs, in terms of USD million, considering historical data for 2010 and 2011, and base year as 2012. The % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 - 2019 has also been provided along with market size estimations.
Browse the full Report: http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html
Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific, and Rest of the World (RoW). The respective market size and forecast till 2019 for each region has also been presented in the report along with the CAGR. In addition, the market overview section of the report provides a qualitative assessment of the market dynamics wherein the drivers, restraints, and opportunities along with market attractiveness and Porter’s Five Forces analysis have been studied.
The competitive landscape section includes market share analysis of the leading players in the branded drugs market for erectile dysfunction treatment, in terms of percentage share in the year 2012. Some of the major players profiled in this report include Pfizer, Inc., Eli Lilly and Co., Bayer AG, Dong-A Pharmaceutical Co. Ltd., and Vivus, Inc.
Request for customization of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1550